Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
8.28
-0.30 (-3.50%)
At close: May 22, 2026, 4:00 PM EDT
8.25
-0.03 (-0.36%)
After-hours: May 22, 2026, 4:10 PM EDT

Xilio Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
4941441574438
Market Cap Growth
32.39%-7.07%187.78%-79.42%-83.15%-
Enterprise Value
-94.34-91.31-4.64-21.38-34.26259.42
Last Close Price
8.288.9613.377.7037.66224.00
PS Ratio
0.920.936.89---
PB Ratio
0.661.152.480.410.702.36
P/TBV Ratio
1.322.122.900.410.700.48
EV/Sales Ratio
--2.09-0.73---
EV/EBITDA Ratio
-2.260.080.280.39-
EV/EBIT Ratio
-2.180.080.270.38-
EV/FCF Ratio
-16.570.250.310.44-
Debt / Equity Ratio
0.070.160.400.220.120.11
Net Debt / Equity Ratio
-1.98-3.70-2.68-0.87-0.95-0.96
Net Debt / EBITDA Ratio
3.283.230.800.421.152.41
Net Debt / FCF Ratio
2.5123.702.560.471.302.17
Asset Turnover
0.340.390.10000
Quick Ratio
3.502.442.032.805.7015.50
Current Ratio
3.592.582.213.025.8915.85
Return on Equity (ROE)
-63.49%-132.53%-214.02%-107.25%-60.62%-84.15%
Return on Assets (ROA)
-28.39%-37.19%-91.79%-79.10%-49.91%-59.00%
Return on Invested Capital (ROIC)
-1683.32%-1533.31%-1532.95%-1582.19%-1326.62%-2495.23%
Return on Capital Employed (ROCE)
-41.26%-59.04%-136.47%-97.09%-55.14%-68.39%
Buyback Yield / Dilution
-24.15%-118.70%-94.61%-0.38%-388.59%-970.34%
Total Shareholder Return
-24.15%-118.70%-94.61%-0.38%-388.59%-970.34%
Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q